Difficulty: Medium
Average Score: 89%
Practice
A 65-year-old man who has already suffered one myocardial infarction because of extensive atherosclerosis is interested in modifying his risk for a second cardiac event. In terms of lipoproteins, which of the following should be modified to reduce the atherogenicity potential?
Correct answer
C
Rationale
The correct answer is C) Low-density lipoprotein (LDL) when considering modifying lipoproteins to reduce atherogenicity potential in a patient with a history of myocardial infarction and extensive atherosclerosis. LDL is often referred to as "bad" cholesterol because high levels of LDL can lead to the buildup of plaque in the arteries, increasing the risk of atherosclerosis and cardiovascular events like heart attacks. By lowering LDL levels through lifestyle modifications or medications, the risk of a second cardiac event can be reduced.
Option A) Chylomicron is not typically a primary target for modification to reduce atherogenicity potential. Chylomicrons are large lipoprotein particles that transport dietary triglycerides from the intestines to the liver and other tissues.
Option B) High-density lipoprotein (HDL) is often referred to as "good" cholesterol because it helps transport cholesterol away from the arteries to the liver for excretion, thereby reducing the risk of atherosclerosis. While increasing HDL levels is beneficial, the primary focus for reducing atherogenicity potential in this context would be on lowering LDL levels.
Option D) Very low-density lipoprotein (VLDL) is another type of lipoprotein that carries triglycerides produced by the liver to the tissues. While VLDL levels can also impact cardiovascular health, LDL is a more direct contributor to atherosclerosis and myocardial infarction in this scenario.
Educationally, understanding the role of different lipoproteins in cardiovascular health is crucial for healthcare providers managing patients with cardiovascular risk factors or a history of heart disease. By targeting LDL reduction through appropriate interventions, such as dietary modifications, exercise, and medications like statins, healthcare providers can help reduce the risk of recurrent cardiovascular events in high-risk patients like the one described in the scenario.
Option A) Chylomicron is not typically a primary target for modification to reduce atherogenicity potential. Chylomicrons are large lipoprotein particles that transport dietary triglycerides from the intestines to the liver and other tissues.
Option B) High-density lipoprotein (HDL) is often referred to as "good" cholesterol because it helps transport cholesterol away from the arteries to the liver for excretion, thereby reducing the risk of atherosclerosis. While increasing HDL levels is beneficial, the primary focus for reducing atherogenicity potential in this context would be on lowering LDL levels.
Option D) Very low-density lipoprotein (VLDL) is another type of lipoprotein that carries triglycerides produced by the liver to the tissues. While VLDL levels can also impact cardiovascular health, LDL is a more direct contributor to atherosclerosis and myocardial infarction in this scenario.
Educationally, understanding the role of different lipoproteins in cardiovascular health is crucial for healthcare providers managing patients with cardiovascular risk factors or a history of heart disease. By targeting LDL reduction through appropriate interventions, such as dietary modifications, exercise, and medications like statins, healthcare providers can help reduce the risk of recurrent cardiovascular events in high-risk patients like the one described in the scenario.